Lantheus Announces FDA Approval of TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer’s Disease

Go back to Lantheus Announces FDA Approval of TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer’s Disease
(NASDAQ: LNTH) Delayed: 100.31 -0.15 (0.15%)
Previous Close $100.46    52 Week High $10.70 
Open $100.50    52 Week Low $1.76 
Day High $100.59    P/E N/A 
Day Low $100.31    EPS $0.00 
Volume 931,763